Relay Therapeutics, Inc. (RLAY) Form 8-K — Nov 4, 2026
Relay Therapeutics reported Q3 2026 results: net loss of $81.7 million ($0.37/share) versus $74.1 million ($0.43/share) a year ago, with R&D expense rising to $77.1 million on higher clinical trial costs. The company ended the quarter with $848.6 million in cash and investments and says runway extends into 2029. Its Phase 3 ReDiscover-2 trial of zovegalisib in 2L breast cancer is on track to complete enrollment in mid-2027, roughly a year ahead of benchmarks. Key catalysts ahead: updated ReInspire data in vascular anomalies in an oral ASH presentation on December 14, 2026, followed by a corporate call with a regulatory update.
Key figures
- Revenue
- 3350000
- Guidance
- Cash sufficient to fund operations into 2029; ReDiscover-2 Phase 3 enrollment completion estimated mid-2027; Phase 3 1L breast cancer trial initiation early 2027
- Total Assets
- 901692000
- Cash Position
- 848642000
- Cash q2 2026
- 910900000
- G and a expense q3 2026
- 13107000
- R and d expense q3 2025
- 68262000
- R and d expense q3 2026
- 77138000
- Weighted avg shares q3 2026
- 219157506
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.